Azienda Ospedaliera "Carlo Poma", Mantova

Abstract

Data on the efficacy and tolerability of dasatinib in the treatment of chronic myeloid leukaemia (CML) derive from studies on extremely selected groups of patients, and so information from very elderly patients and patients with severe comorbid conditions are very scarce. This can lead to suboptimal or inappropriate therapeutic choices in such patients, with a significant impact on their quality of life and ease of management. We report here the case of a 92-year old patient with accelerated phase CML who was refractory to imatinib therapy, had severe comorbid conditions and required frequent admissions to hospital after progression of her disease. The patient was treated with standard doses of dasatinib and responded rapidly to this therapy: further hospital admissions were thereby avoided and the patient’s quality of life was improved.

Keywords

• Dasatinib
• QoL
• elderly